Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH001 for Moderate to Severe Atopic Dermatitis (Small-Sample Study)
ChiCTR2600120696Phase 2Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of xkh001 in atopic dermatitis (AD), sponsored by Hangzhou First People's Hospital. Primary endpoints: Eczema Area and Severity Index (EASI), Single-cell RNA sequencing of immune cells in peripheral blood and skin lesion tissues and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
xkh001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600120696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120696.